Research programme: antifungal therapeutics - Daewoong Pharmaceutical
Alternative Names: DWJ205; DWP06081; DWP07118Latest Information Update: 28 Dec 2022
At a glance
- Originator Daewoong Pharmaceutical
- Class Antifungals; Azoles; Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Mycoses
Most Recent Events
- 28 Dec 2022 Discontinued for Mycoses in South Korea (unspecified route)
- 28 Jan 2020 No recent reports of development identified for research development in Mycoses in South Korea
- 29 Jan 2018 DWJ2015 is still in early research phase for Fungal infection (Daewoong Pharmaceuticals pipeline, January 2018)